Acadian Asset Management LLC Cytom X Therapeutics, Inc. Transaction History

Acadian Asset Management LLC

$32.5 Billion
Q2 2024

A detailed history of Acadian Asset Management LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 2,728,569 shares of CTMX stock, worth $2.73 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,728,569

Previous 2,690,830 1.4%

Holding current value

$2.73 Million

Previous $5.86 Million 43.31%

% of portfolio

0.01%

Previous 0.02%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$1.21 - $5.13 $45,664 - $193,601	37,739 Added 1.4%	2,728,569 $3.32 Million
Q1 2024 May 10, 2024	BUY	$1.41 - $2.74 $62,942 - $122,313	44,640 Added 1.69%	2,690,830 $5.86 Million
Q3 2023 Nov 13, 2023	SELL	$1.26 - $1.87 $9,306 - $13,811	-7,386 Reduced 0.28%	2,646,190 $3.41 Million
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $1 Million - $1.6 Million	814,350 Added 44.28%	2,653,576 $3.85 Million
Q2 2022 Aug 09, 2022	BUY	$1.53 - $2.89 $1.46 Million - $2.76 Million	954,119 Added 107.8%	1,839,226 $3.37 Million
Q1 2022 May 12, 2022	BUY	$2.67 - $4.68 $1.27 Million - $2.22 Million	473,885 Added 115.24%	885,107 $2.36 Million
Q4 2021 Feb 10, 2022	SELL	$3.87 - $7.39 $1.12 Million - $2.14 Million	-289,768 Reduced 41.34%	411,222 $1.78 Million
Q3 2021 Nov 12, 2021	SELL	$4.32 - $6.43 $1.5 Million - $2.24 Million	-348,149 Reduced 33.18%	700,990 $3.57 Million
Q2 2021 Aug 11, 2021	BUY	$6.33 - $9.91 $646,786 - $1.01 Million	102,178 Added 10.79%	1,049,139 $6.64 Million
Q1 2021 May 11, 2021	BUY	$6.6 - $9.0 $1.71 Million - $2.33 Million	259,071 Added 37.66%	946,961 $7.32 Million
Q4 2020 Feb 11, 2021	BUY	$6.47 - $7.9 $683,717 - $834,832	105,675 Added 18.15%	687,890 $4.51 Million
Q3 2020 Nov 09, 2020	BUY	$6.55 - $8.83 $1.87 Million - $2.53 Million	286,216 Added 96.69%	582,215 $3.87 Million
Q2 2020 Aug 12, 2020	BUY	$7.4 - $14.64 $176,238 - $348,666	23,816 Added 8.75%	295,999 $2.47 Million
Q1 2020 May 11, 2020	BUY	$3.61 - $8.6 $247,794 - $590,312	68,641 Added 33.72%	272,183 $2.09 Million
Q4 2019 Feb 06, 2020	BUY	$5.17 - $8.91 $568,229 - $979,289	109,909 Added 117.38%	203,542 $1.69 Million
Q3 2019 Nov 07, 2019	SELL	$7.38 - $12.25 $414,822 - $688,560	-56,209 Reduced 37.51%	93,633 $691,000
Q2 2019 Aug 08, 2019	BUY	$9.35 - $11.41 $276,460 - $337,370	29,568 Added 24.58%	149,842 $1.68 Million
Q1 2019 May 09, 2019	BUY	$9.5 - $19.16 $1.14 Million - $2.3 Million	120,274 New	120,274 $1.29 Million
Q3 2018 Oct 30, 2018	SELL	$18.04 - $26.41 $917,929 - $1.34 Million	-50,883 Closed	0 $0
Q2 2018 Jul 24, 2018	SELL	$21.38 - $29.68 $479,040 - $665,010	-22,406 Reduced 30.57%	50,883 $1.16 Million
Q1 2018 Apr 12, 2018	BUY	$21.76 - $34.22 $1.59 Million - $2.51 Million	73,289 New	73,289 $2.09 Million
Q4 2017 Jan 18, 2018	SELL	$19.0 - $23.09 $30,552 - $37,128	-1,608 Closed	0 $0
Q3 2017 Oct 13, 2017	BUY	$13.53 - $18.17 $21,756 - $29,217	1,608	1,608 $29,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.4M

Call Options Held

22.3K

Put Options Held

22.9K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account

Acadian Asset Management LLC Cytom X Therapeutics, Inc. Transaction History